Biotech veteran David Hung talks about the launch of IBTROZI in ROS1 positive non-small cell lung cancer, and what's next for Nuvation Bio
He discusses the clinical profile of IBTROZI, how the launch is going, and describes other work the company is doing in precision medicine. Plus, his take on the biotech environment currently.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.